Association of lopinavir concentrations with plasma lipid or glucose concentrations in HIV-infected South Africans: a cross sectional study

Simple item page
dc.contributor.authorSinxadi, Phumlaen_ZA
dc.contributor.authorMcIlleron, Helenen_ZA
dc.contributor.authorDave, Joelen_ZA
dc.contributor.authorSmith, Peteren_ZA
dc.contributor.authorLevitt, Naomien_ZA
dc.contributor.authorMaartens, Garyen_ZA
dc.date.accessioned2015-11-23T12:08:34Z
dc.date.available2015-11-23T12:08:34Z
dc.date.issued2012en_ZA
dc.description.abstractBACKGROUND: Dyslipidaemia and dysglycaemia have been associated with exposure to ritonavir-boosted protease inhibitors. Lopinavir/ritonavir, the most commonly used protease inhibitor in resource-limited settings, often causes dyslipidaemia. There are contradictory data regarding the association between lopinavir concentrations and changes in lipids.AIM:To investigate associations between plasma lopinavir concentrations and lipid and glucose concentrations in HIV-infected South African adults. METHODS: Participants stable on lopinavir-based antiretroviral therapy were enrolled into a cross-sectional study. After an overnight fast, total cholesterol, triglycerides, and lopinavir concentrations were measured and an oral glucose tolerance test was performed. Regression analyses were used to determine associations between plasma lopinavir concentrations and fasting and 2 hour plasma glucose, fasting cholesterol, and triglycerides concentrations. RESULTS: There were 84 participants (72 women) with a median age of 36 years. The median blood pressure, body mass index and waist: hip ratio were 108/72 mmHg, 26 kg/m2 and 0.89 respectively. The median CD4 count was 478 cells/mm3. Median duration on lopinavir was 18.5 months. The median (interquartile range) lopinavir concentration was 8.0 (5.2 to 12.8) mug/mL. Regression analyses showed no significant association between lopinavir pre-dose concentrations and fasting cholesterol (beta-coefficient 0.04 (95% CI 0.07 to 0.00)), triglycerides (beta-coefficient 0.01 (95% CI 0.04 to 0.02)), fasting glucose (beta-coefficient 0.01 (95% CI 0.04 to 0.02)), or 2-hour glucose concentrations (beta-coefficient 0.02 (95% CI 0.09 to 0.06)). Lopinavir concentrations above the median were not associated with presence of dyslipidaemia or dysglycaemia. CONCLUSIONS: There was no association between lopinavir plasma concentrations and plasma lipid and glucose concentrations.en_ZA
dc.identifier.apacitationSinxadi, P., McIlleron, H., Dave, J., Smith, P., Levitt, N., & Maartens, G. (2012). Association of lopinavir concentrations with plasma lipid or glucose concentrations in HIV-infected South Africans: a cross sectional study. <i>AIDS Research and Therapy</i>, http://hdl.handle.net/11427/15249en_ZA
dc.identifier.chicagocitationSinxadi, Phumla, Helen McIlleron, Joel Dave, Peter Smith, Naomi Levitt, and Gary Maartens "Association of lopinavir concentrations with plasma lipid or glucose concentrations in HIV-infected South Africans: a cross sectional study." <i>AIDS Research and Therapy</i> (2012) http://hdl.handle.net/11427/15249en_ZA
dc.identifier.citationSinxadi, P. Z., McIlleron, H. M., Dave, J. A., Smith, P. J., Levitt, N. S., & Maartens, G. (2012). Association of lopinavir concentrations with plasma lipid or glucose concentrations in HIV-infected South Africans: a cross sectional study. AIDS research and therapy, 9(1), 1-6.en_ZA
dc.identifier.ris TY - Journal Article AU - Sinxadi, Phumla AU - McIlleron, Helen AU - Dave, Joel AU - Smith, Peter AU - Levitt, Naomi AU - Maartens, Gary AB - BACKGROUND: Dyslipidaemia and dysglycaemia have been associated with exposure to ritonavir-boosted protease inhibitors. Lopinavir/ritonavir, the most commonly used protease inhibitor in resource-limited settings, often causes dyslipidaemia. There are contradictory data regarding the association between lopinavir concentrations and changes in lipids.AIM:To investigate associations between plasma lopinavir concentrations and lipid and glucose concentrations in HIV-infected South African adults. METHODS: Participants stable on lopinavir-based antiretroviral therapy were enrolled into a cross-sectional study. After an overnight fast, total cholesterol, triglycerides, and lopinavir concentrations were measured and an oral glucose tolerance test was performed. Regression analyses were used to determine associations between plasma lopinavir concentrations and fasting and 2 hour plasma glucose, fasting cholesterol, and triglycerides concentrations. RESULTS: There were 84 participants (72 women) with a median age of 36 years. The median blood pressure, body mass index and waist: hip ratio were 108/72 mmHg, 26 kg/m2 and 0.89 respectively. The median CD4 count was 478 cells/mm3. Median duration on lopinavir was 18.5 months. The median (interquartile range) lopinavir concentration was 8.0 (5.2 to 12.8) mug/mL. Regression analyses showed no significant association between lopinavir pre-dose concentrations and fasting cholesterol (beta-coefficient 0.04 (95% CI 0.07 to 0.00)), triglycerides (beta-coefficient 0.01 (95% CI 0.04 to 0.02)), fasting glucose (beta-coefficient 0.01 (95% CI 0.04 to 0.02)), or 2-hour glucose concentrations (beta-coefficient 0.02 (95% CI 0.09 to 0.06)). Lopinavir concentrations above the median were not associated with presence of dyslipidaemia or dysglycaemia. CONCLUSIONS: There was no association between lopinavir plasma concentrations and plasma lipid and glucose concentrations. DA - 2012 DB - OpenUCT DO - 10.1186/1742-6405-9-32 DP - University of Cape Town J1 - AIDS Research and Therapy LK - https://open.uct.ac.za PB - University of Cape Town PY - 2012 T1 - Association of lopinavir concentrations with plasma lipid or glucose concentrations in HIV-infected South Africans: a cross sectional study TI - Association of lopinavir concentrations with plasma lipid or glucose concentrations in HIV-infected South Africans: a cross sectional study UR - http://hdl.handle.net/11427/15249 ER - en_ZA
dc.identifier.urihttp://hdl.handle.net/11427/15249
dc.identifier.urihttp://dx.doi.org/10.1186/1742-6405-9-32
dc.identifier.vancouvercitationSinxadi P, McIlleron H, Dave J, Smith P, Levitt N, Maartens G. Association of lopinavir concentrations with plasma lipid or glucose concentrations in HIV-infected South Africans: a cross sectional study. AIDS Research and Therapy. 2012; http://hdl.handle.net/11427/15249.en_ZA
dc.language.isoengen_ZA
dc.publisherBioMed Central Ltden_ZA
dc.publisher.departmentDivision of Clinical Pharmacologyen_ZA
dc.publisher.facultyFaculty of Health Sciencesen_ZA
dc.publisher.institutionUniversity of Cape Town
dc.rightsThis is an Open Access article distributed under the terms of the Creative Commons Attribution Licenseen_ZA
dc.rights.holderSinxadi et al.; licensee BioMed Central Ltd. 2012en_ZA
dc.rights.urihttp://creativecommons.org/licenses/by/2.0en_ZA
dc.sourceAIDS Research and Therapyen_ZA
dc.source.urihttp://aidsrestherapy.biomedcentral.com/en_ZA
dc.subject.otherLopinaviren_ZA
dc.subject.otherHypercholesterolaemiaen_ZA
dc.subject.otherHypertriglyceridaemiaen_ZA
dc.subject.otherImpaired glucose metabolismen_ZA
dc.subject.otherAntiretroviral therapyen_ZA
dc.subject.otherPharmacokineticsen_ZA
dc.titleAssociation of lopinavir concentrations with plasma lipid or glucose concentrations in HIV-infected South Africans: a cross sectional studyen_ZA
dc.typeJournal Articleen_ZA
uct.type.filetypeText
uct.type.filetypeImage
uct.type.publicationResearchen_ZA
uct.type.resourceArticleen_ZA
Files
Original bundle
Now showing 1 - 1 of 1
Thumbnail Image
Name:
Sinxadi_Association_of_lopinavir_2012.pdf
Size:
344.06 KB
Format:
Adobe Portable Document Format
Description:
Download
Collections
Journal Articles